Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cuprina Holdings (Cayman)CUPR -2.51%10 Operating Margin % is -10,233.33% as of Dec. 2025. GuruFocus rates CUPR with a GF Score™ of 10/100. The stock has 6 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Cuprina Holdings (Cayman) ranks worse than 98.16% on this metric.
The historical rank and industry rank for Cuprina Holdings (Cayman)'s Operating Margin % or its related term are showing as below:
CUPR'
s Operating Margin % Range Over the Past 10 Years
Min: -9097.44 Med: -1980.95 Max: -883.72
Current: -9097.44
CUPR's Operating Margin % is ranked worse than 98.16% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 3.17
vs CUPR: -9097.44
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Cuprina Holdings (Cayman) Operating Margin % Related Terms
Cuprina Holdings (Cayman) Operating Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CUPR vs BNGO, UEEC, FEMY: Operating Margin % Comparison
For the Medical Instruments & Supplies subindustry, Cuprina Holdings (Cayman)'s Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cuprina Holdings (Cayman) Operating Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cuprina Holdings (Cayman)'s Operating Margin % distribution charts can be found below:
* The bar in red indicates where Cuprina Holdings (Cayman)'s Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Cuprina Holdings (Cayman)'s Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Margin % of -10,233.33% mean?
Cuprina Holdings (Cayman) (CUPR) has a Operating Margin % of -10,233.33% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Cuprina Holdings (Cayman) and its competitors. According to the industry distribution chart, Cuprina Holdings (Cayman) ranks #802 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 98.2%.
Is Cuprina Holdings (Cayman)'s Operating Margin % too high?
Cuprina Holdings (Cayman)'s current Operating Margin % is -10,233.33%. Based on the distribution chart, Cuprina Holdings (Cayman) ranks #802 out of 817 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Cuprina Holdings (Cayman) has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Cuprina Holdings (Cayman)'s Operating Margin % compare to BNGO and UEEC?
According to the Medical Devices & Instruments industry distribution chart, Cuprina Holdings (Cayman) ranks #802 out of 817 companies for Operating Margin %. This places Cuprina Holdings (Cayman) in the lower half of its industry. The industry median Operating Margin % is 3.17. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Devices & Instruments company?
The median Operating Margin % among Medical Devices & Instruments companies is 3.17, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Cuprina Holdings (Cayman) and its competitors. For the Medical Devices & Instruments industry, the median Operating Margin % is 3.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cuprina Holdings (Cayman)'s current Operating Margin % is -10,233.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cuprina Holdings (Cayman) stock overvalued right now?
Cuprina Holdings (Cayman) (CUPR) has a current Operating Margin % of -10,233.33%. The current Operating Margin % is -10,233.33%. Cuprina Holdings (Cayman)'s overall GF Score™ is 10/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Cuprina Holdings (Cayman) (CUPR), the current Operating Margin % is -10,233.33% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cuprina Holdings (Cayman) Ltd is a biomedical and biotechnology company that is dedicated to the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. It manufactured and distributed a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as Maggot Debridement Therapy, or MDT, which is an effective alternative to surgical debridement.
10GF Score
Get the complete analysis for CUPR
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CUPR has been successfully added to your 
